Clinical study confirms effectiveness of tennis elbow treatment
THE ROADHOUSE PHARMACY: Orthocell Limited (ASX: OCC) released results from a long-term clinical study into the company’s Ortho-ATI treatment for tennis elbow.
Orthocell said the results had provided evidence of the durability and long term success of this treatment.
The company claimed the clinical study showed grip strength scores of patients suffering from a severe form of tennis elbow, called chronic lateral epicondylitis, improved by an average 84 per cent at one year after treatment and 207 per cent at an average of 4.5 years after they underwent the Orthocell procedure.
This data represents the first long term efficacy data for a stem cell based tendon regeneration treatment, that has been published globally.
“Ortho-ATI has proven itself to be an effective and durable long-term solution for degenerate, treatment-resistant tendons,” Orthocell managing director Paul Anderson said in the company’s announcement to the UAstyralian Securities Exchange.
Tennis elbow is a painful condition caused by damage and degeneration of tendons in the elbow due to overuse.
Current treatments such as steroid injections are limited in their effectiveness and fail to address the underlying cause of the egeneration.
Orthocell explained Ortho-ATI treats tennis elbow by extracting a small sample of patient’s healthy tendon stem cells, culturing and expanding them in a laboratory and then re-injecting the cells into the damaged tissue to help it regenerate and to reduce pain and inflammation.
“The results are very positive and encouraging for patients affected by painful and debilitating degenerate tendon injuries,” Anderson continued.
“They show long-term, sustained and statistically significant positive results in a very difficult to treat group of chronic patients.”
The study found a single injection of a patient’s cultured tendon stem cells considerably improved clinical function at the 3 to 5 year follow up of patients who had previously undergone an unsuccessful course of conservative treatment such as exercise and corticosteroid injections.
The study was undertaken at the University of Western Australia in conjunction with Sir Charles Gairdner Hospital in WA and was led by Orthocell’s consultant Chief Scientific Officer, Professor M.H. Zheng and orthopaedic surgeon Associate Professor Alan Wang.
Ortho-ATI is available in Australia and New Zealand for patients who have failed conservative treatment options such as corticosteroid injections and exercise programs and have ongoing symptoms.
Website: www.orthocell.com.au